Pediatric Microdose and Microtracer Studies Using 14C in Europe

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 3, 2015, Pages 234-237

  Turner, M A ^a   Mooij, M G ^b   Vaes, W H J ^c   Windhorst, A D ^d   Hendrikse, N H ^d   Knibbe, C A J ^e,f   Korgvee L T ^g   Maruszak, W ^h   Grynkiewicz, G ^h   Garner, R C ⁱ   Tibboel, D ^b   Park, B K ^a   De Wildt, S N ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c TNO   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Leiden Academic Centre for Research   (Netherlands)

^f ST ANTONIUS HOSPITAL   (Netherlands)

^g UNIVERSITY OF TARTU   (Estonia)

^h INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

ⁱ UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; TRACER; CARBON; DRUG;

CLINICAL TRIAL (TOPIC); DRUG COST; DRUG MICRODOSE; ETHICS; HUMAN; INFORMED CONSENT; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIOACTIVITY; REVIEW; RISK ASSESSMENT; AGE; CHILD; DOSE CALCULATION; DOSE RESPONSE; DRUG APPROVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ECONOMICS; EUROPE; GOVERNMENT REGULATION; INFANT; LEGISLATION AND JURISPRUDENCE; METABOLISM; NEWBORN; PATIENT SAFETY; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PRESCHOOL CHILD; RISK FACTOR;

AGE FACTORS; CARBON RADIOISOTOPES; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE I AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG APPROVAL; DRUG COSTS; DRUG DOSAGE CALCULATIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EUROPE; GOVERNMENT REGULATION; HUMANS; INFANT; INFANT, NEWBORN; PATIENT SAFETY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; RISK ASSESSMENT; RISK FACTORS;

EID: 84946403428     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.163     Document Type: Review

References (10)

1. Kearns, G.L. et al. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157-1167 (2003).
2. Lappin, G., Noveck, R. & Burt, T. Microdosing and drug development: past, present and future. Expert Opin. Drug Metab. Toxicol. 9, 817-834 (2013).
3. Salehpour, M., Possnert, G. & Bryhni, H. Subattomole sensitivity in biological accelerator mass spectrometry. Anal. Chem. 80, 3515-3621 (2008).
4. The European Parliament, The Council of the European Union. Regulation (EU) No 1901/2006 on medicinal products for paediatric use and amending Regulation (EEC) No 1768/92, Directive 2001/20/ EC, Directive 2001/83/EC and Regulation (EC) No 726/2004. In: The European Parliament, editor. 1901/2006; 2006.
5. Mooij, M.G. et al. Pediatric microdose study of [14C] paracetamol to study drug metabolism using accelerated mass spectrometry: proof of concept. Clin. Pharmacokinet. 53, 1045-1051 (2014).
6. Garner, R.C. et al. Observational infant exploratory [14C] paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis. Br. J. Clin. Pharmacol. (2015); e-pub ahead of print.
7. Vuong, L.T., Blood, A.B., Vogel, J.S., Anderson, M.E. & Goldstein, B. Applications of accelerator MS in pediatric drug evaluation. Bioanalysis 4, 1871-1882 (2012).
8. Kleiber, N. et al. Ethics of drug research in the pediatric intensive care unit. Paediatr. Drugs. 17, 43-53 (2015).
9. Lappin, G. et al. Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers. Eur. J. Pharm. Sci. 43, 141-150 (2011).
10. Hohmann, N. et al. Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. Br. J. Clin. Pharmacol. 79, 278-285 (2015).